Discovery of Novel Nonpeptidic PAR2 Ligands.

Proteinase-activated receptor 2 (PAR2) is a class A G protein-coupled receptor whose activation has been associated with inflammatory diseases and cancer, thus representing a valuable therapeutic target. Pathophysiological roles of PAR2 are often characterized using peptidic PAR2 agonists. Peptidic ligands are frequently unstable in vivo and show poor bioavailability, and only a few approaches toward drug-like nonpeptidic PAR2 ligands have been described. The herein-described ligand 5a (IK187) is a nonpeptidic PAR2 agonist with submicromolar potency in a functional assay reflecting G protein activation. The ligand also showed substantial β-arrestin recruitment. The development of the compound was guided by the crystal structure of PAR2, when the C-terminal end of peptidic agonists was replaced by a small molecule based on a disubstituted phenylene scaffold. IK187 shows preferable metabolic stability and may serve as a lead compound for the development of nonpeptidic drugs addressing PAR2. Copyright © 2020 American Chemical Society.

Citation

Ilona Klösel, Maximilian F Schmidt, Jonas Kaindl, Harald Hübner, Dorothee Weikert, Peter Gmeiner. Discovery of Novel Nonpeptidic PAR2 Ligands. ACS medicinal chemistry letters. 2020 Jun 11;11(6):1316-1323

PMID: 32551018

search → result